Please use this identifier to cite or link to this item: https://doi.org/10.18632/oncotarget.8223
Title: ANO1 protein as a potential biomarker for esophageal cancer prognosis and precancerous lesion development prediction
Authors: Shang, L
Hao, J.-J
Zhao, X.-K
He, J.-Z
Shi, Z.-Z
Liu, H.-J
Wu, L.-F
Jiang, Y.-Y 
Shi, F
Yang, H
Zhang, Y
Liu, Y.-Z
Zhang, T.-T
Xu, X
Cai, Y
Jia, X.-M
Li, M
Zhan, Q.-M
Li, E.-M
Wang, L.-D
Wei, W.-Q
Wang, M.-R
Keywords: anoctamin 1
membrane protein
unclassified drug
ANO1 protein, human
anoctamin 1
tumor marker
tumor protein
adult
Article
cancer growth
cancer prognosis
cancer staging
cancer survival
cohort analysis
controlled study
esophagus biopsy
esophagus cancer
female
human
human tissue
immunohistochemistry
lymph node metastasis
major clinical study
male
middle aged
overall survival
precancer
predictive value
protein analysis
protein expression
protein function
survival prediction
biosynthesis
disease exacerbation
esophagus
esophagus tumor
Kaplan Meier method
metabolism
pathology
precancer
prognosis
squamous cell carcinoma
Anoctamin-1
Biomarkers, Tumor
Carcinoma, Squamous Cell
Disease Progression
Esophageal Neoplasms
Esophagus
Female
Humans
Immunohistochemistry
Kaplan-Meier Estimate
Male
Middle Aged
Neoplasm Proteins
Precancerous Conditions
Prognosis
Issue Date: 2016
Citation: Shang, L, Hao, J.-J, Zhao, X.-K, He, J.-Z, Shi, Z.-Z, Liu, H.-J, Wu, L.-F, Jiang, Y.-Y, Shi, F, Yang, H, Zhang, Y, Liu, Y.-Z, Zhang, T.-T, Xu, X, Cai, Y, Jia, X.-M, Li, M, Zhan, Q.-M, Li, E.-M, Wang, L.-D, Wei, W.-Q, Wang, M.-R (2016). ANO1 protein as a potential biomarker for esophageal cancer prognosis and precancerous lesion development prediction. Oncotarget 7 (17) : 24374-24382. ScholarBank@NUS Repository. https://doi.org/10.18632/oncotarget.8223
Rights: Attribution 4.0 International
Abstract: Objectives: Anoctamin 1 (ANO1) has been found to be overexpressed in esophageal squamous cell carcinoma (ESCC) in our previous study. Herein we showed the clinical relevance of ANO1 alterations with ESCC and esophageal precancerous lesion progression. Results: ANO1 was detected in 38.1% (109/286) and 25.4% (77/303) of tumors in the two cohorts, but in none of morphologically normal operative margin tissues. ANO1 expression was significantly associated with a shorter overall survival (OS), especially in patients with moderately differentiated and stage IIA tumors. In 499 iodine-unstained biopsies from the endoscopic screening cohort in 2005-2007, all the 72 pathologically normal epithelial mucosa presented negative immunostaining, whereas ANO1 expression was observed in 3/11 tumors and 5/231 intraepithelial lesions. 7/8 ANO1-positive cases had developed unfavorable outcomes revealed by endoscopic follow-up in 2012. Analysis of another independent cohort of 148 intraepithelial lesions further confirmed the correlation between ANO1 expression and progression of precancerous lesions. 3/4 intraepithelial lesions with ANO1 expression had developed ESCC within 4-9 years after the initial endoscopic examination. Methods: Immunohistochemistry (IHC) was performed to examine ANO1 expression in surgical ESCC specimens and two independent cohorts of esophageal biopsies from endoscopic screening in high-incidence area of ESCC in northern China. Association between ANO1 expression, clinico-pathologic parameters, and the impact on overall survival was analyzed. Conclusions: Positive ANO1 is a promising biomarker to predict the unfavorable outcome for ESCC patients. More importantly, it can predict disease progression of precancerous lesions.
Source Title: Oncotarget
URI: https://scholarbank.nus.edu.sg/handle/10635/179931
ISSN: 19492553
DOI: 10.18632/oncotarget.8223
Rights: Attribution 4.0 International
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_18632_oncotarget_8223.pdf3.06 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

21
checked on Jan 14, 2021

Page view(s)

18
checked on Jan 14, 2021

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons